ŌURA’s Post

This is a big milestone for ŌURA which through a strategic partnership with Dexcom will provide a first-of-its-kind metabolic health management experience. Dexcom also invested $75 million in Oura’s Series D funding, bringing Pura’s valuation to more than $5 billion. A big day for wearables 👀📈

🚀 Big news in the health tech world! ŌURA and Dexcom are joining forces to integrate their cutting-edge technologies, offering users deeper insights into how their activity, sleep, nutrition, and glucose levels all connect by combining ŌURA’s wearable health ring with Dexcom’s continuous glucose monitoring, this collaboration empowers individuals to make data-driven decisions that can have a lasting impact on their health and well-being. Looking forward to seeing how this integration evolves and how it will shape the future of wellness. 🙌#HealthTech #Wearables #GlucoseMonitoring #HolisticHealth #Wellness #Innovation #StartupJourney #FutureOfHealth

Can we finally bring together the tools people need to reverse the wave of #type2diabetes? Working at Nutrisense, I saw first hand the impact of sleep and physical activity on #bloodglucose and #metabolichealth. Among our users, people with #prediabetes were especially likely to benefit from regulating their sleep and incorporating physical activity into their day. But behavior change is really hard, especially when you don't see the direct impact of each action. This is why I am so excited that ŌURA and Dexcom are partnering to integrate CGM data with the Oura app. This is a huge win for consumers! ŌURA is a best-in-class sleep and fitness tracker, and their app is a joy to use. Dexcom’s continuous glucose monitors are now available over the counter. I have high confidence that Oura can bring all the data together to motivate and sustain behavior change for consumers who can really benefit from lifestyle changes to maintain a healthy metabolism. I’m excited to see where this partnership goes!

Several years ago, I experimented with this concept in a more conventional way, trying to piece together insights from separate platforms. While the experience was clunky and cumbersome, it had a profound impact on my behavior as both an athlete and a professional. During my studies in AI and Digital Business, as well as through capstone projects, I even explored whether there was a business opportunity in this space. This is why I can only applaud the partnership between ŌURA and Dexcom where personalized health and well-being are being democratized and simplified. It’s inspiring to see innovative solutions that leverage data and technology to empower individuals to elevate their health journey and maximize their potential with ease. #PersonalizedHealth #DigitalHealth #AI #WearableTechnology #HealthInnovation #ŌURA #Dexcom #HealthTech #Wellbeing #PerformanceOptimization #DigitalBusiness #AthleteMindset #MYPo #Maximizeyourpotential #healthcare #prevention

Pumped to share that ŌURA is partnering with Dexcom. This collaboration brings together Dexcom’s continuous glucose monitoring (CGM) technology with the Oura Ring’s robust suite of insights, spanning sleep, activity, readiness, heart rate variability, temperature trends, and more. Imagine having the power to connect glucose levels with nuanced insights like how restorative your sleep was, how balanced your activity and recovery cycles are, or even how your body responds to stress over time. This partnership has the potential to deliver unprecedented clarity, empowering users with actionable feedback to make real-time, meaningful changes to their health and well-being. Proud to be part of a team that’s redefining the role of wearables in healthcare.

Market Movers Update! Here's your daily rundown.⁣ Top 3 Market Gainers: Unusual Machines, Inc. \(UMAC\), from the Electronic technology sector, skyrocketed by 84.51%. Uncover more \[here\]\(https://lnkd.in/eHPqmX_S). In Health technology, Cyclerion Therapeutics, Inc. \(CYCN\) soared by 58.82%. Learn more \[here\]\(https://lnkd.in/e9ZKvXjv). Completing the trio, Procaps Group, S.A. \(PROC\) witnessed a healthy rise of 53.68%. Read more \[here\]\(https://lnkd.in/eNPMuPAP Top 3 Market Losers: Symbotic Inc. \(SYM\) from the Producer manufacturing sector saw a steep drop of 35.86%. Get details \[here\]\(https://lnkd.in/e6bgFT7q). Celularity Inc. \(CELU\), a Commercial services sector player, lost 29.47%. More updates \[here\]\(https://lnkd.in/eWagwx4V). Finally, Palladyne AI Corp. \(PDYN\) from the Producer manufacturing sector declined by 26.07%. Find more \[here\]\(https://lnkd.in/eKsva-nd For more information, please visit our website: https://lnkd.in/ew885w3r or read our detailed Medium post here: https://lnkd.in/eB82ZVAF This update is for informational purposes only and does not constitute trading advice. Stay tuned for more insights, and happy trading!Tags: #zimtra #news 📊 #finance 💰 #markets 📈 #tradingupdate #insights 🔍 #stocks #economy 🌍 #investment 💼 #traderlife #marketnews #financialnews

Martin Picard 2h A revolution in healthcare is much needed This is one piece of the puzzle Mark Hyman, M.D. This is not just another announcement. Over the past few months, you've heard me talk about @function . This isn’t merely about new investors; it's a signal from some of the world's top institutions that empowering you to take control of your health outside the doctor’s office is critical. We’ve secured a $53M investment led by top investor Andreessen Horowitz. Early cancer detection is critical. Getting ahead of heart disease is critical. Understanding your hormones is critical. This investment ensures we can scale this revolutionary approach to reach billions of people. We've already seen countless stories of how Function Health has saved and transformed lives. A 44-year-old father of two discovered prostate cancer in stage one. A 51-year-old mother of four discovered ovarian cancer just in time before she was symptomatic. A 35-year-old fit man revealed a critical heart disease risk that typical physicals never caught. Over 60% of our members have a nutrient deficiency. Over 30% of our members are showing autoimmunity signals. This is about people's lives. And in each case, Function was there to help them take control. We've designed Function to be the easiest and fastest way to take charge of your health, starting with 100+ lab tests that provide an extremely comprehensive picture of what's actually happening inside your body. My career, beyond being a practicing physician, has been dedicated to educating people like you about your health. This is the next level, beyond just writing books. I'm tirelessly working to ensure millions have access to the same high-level healthcare that has been available to wealthy people with concierge doctors—and then going far beyond that. This is just the beginning. We built Function for you. It's time you own your health. https://lnkd.in/egZzR8cx

### Medifast: A Look at the Pros and Cons of Investing in a Leading Weight Management Provider 🌟 Don't Miss Out on this Opportunity! 🌟 Summary: Medifast, a renowned provider of weight management products and services, has recently experienced a significant drop in its stock prices, hitting its 20th 5-year low. With an astonishing decline of 82% during this period, investing in this company may appear either smart or foolish. Let's explore both perspectives to help you make an informed decision. ⭐ The Upside: Reasons to Consider Investing ⭐ 1. Market Position: Medifast is a leading player in the weight management industry, offering trusted products and services to millions worldwide. 2. Growth Potential: Although facing a current market downturn, Medifast has the potential for a turnaround. With strategic initiatives and product innovations, they could regain their market share. 3. Value Opportunity: Buying Medifast stock at its lowest point in years presents an opportunity for potential future gains if the company bounces back. ⭐ The Downside: Potential Risks to Consider ⭐ 1. Financial Challenges: The continuous decline in stock prices indicates underlying financial difficulties that may take time to resolve. 2. Competitive Landscape: Medifast faces intense competition from various other weight management companies, which could hinder their ability to regain dominance. 3. Market Uncertainty: The weight management industry can be sensitive to market trends and consumer preferences, making it inherently volatile. 📣 Take Action Now! 💪 Investing in Medifast at its current low price comes with risks, but also the potential for significant rewards. By conducting thorough research and consulting with financial professionals, you can make an educated decision that aligns with your long-term investment goals. Don't let fear of missing out prevent you from exploring this opportunity! #hsa #investing #healthcare #health #family #wellness 💼💰📈

I am not a Democrat - most Democrat politicians are owned by corporate interests, I am voting Green Party of the United States this election. But Senator Bernie Sanders Campaign Office is right to grill Novo Nordisk's CEO. Novo Nordisk is robbing the American healthcare system blind, hurting patients like my mother-in-law who can not even get Ozempic for its on-label use, and it is being used off-label for weight loss - which actually has been shown to wipe out muscle (this is why patients that lose weight on Ozempic look like skeletons 💀 😢 ). This needs to stop - and I am happy to work with Senator Sanders and Friends of Bernie Sanders if they need additional analytics support. Most people are terrible at healthcare data analytics and use the confusion to keep things as is. We need to all fix this or America will keep losing with its Disease Care system. We need a Health Care system, starting with earlier diagnoses. Exact Sciences and Quest Diagnostics are working hard to deliver earlier Dxs (diagnoses) for all patients so they can receive the right prescriptions (Rxs). Novo Nordisk turns a blind eye to its awful culture & off-label use of its drugs. There are companies like Novo Nordisk (NVO: Denmark), Sanofi (France), GSK (London), and others which are based in Europe or ex-US countries. They game the system, make tons of money off of American taxpayers & veterans, and pay their executives tons of cash they don't deserve. Most biopharma companies have bloated sales forces given that younger doctors prefer the all-digital experience and do not want to spend time talking to sales reps when they could be talking to patients. Specialty sales reps - such as in Oncology - are typically more experienced, intelligent, and are worth the salaries & compensation. Bad ones are not & need to be fired ASAP. A bad sales reprepresentative is a compliance nightmare for any company. General sales reps - such as those that target Primary Care Physicians, Pediatricians, Dermatologists, et cetera, generally are not worth the cash. One of my former bosses, a Chief Commercial Officer in the US, once joined that "Denmark is a small socialist country that does not understand the American healthcare system". On the contrary, I told that boss they do - and this price gouging on Ozempic for the USA versus Denmark & other wealthy countries is ridiculous. Dear Bernie: let me know how I can help! I will email you. I am voting Green Party - perhaps you will join the Green Party & take this on before you retire from the State of Vermont? Cheers, ~Jeff Conroy 🌎 ~~Global HC Analytics LLC, Founder and Biopharma Forecasting Expert. GHCA is a small, private consultancy that supports small biotech companies with offices in the US. We started as a part-time consultancy but are quickly converting to a HealthCare ThinkTank that Engineers New solutions in Data Analytics to identify wasteful spending in the American healthcare system - the Globe's #1 employer.

Did you know that 30 million Americans are affected by overestimated blood pressure, leading to an average $135,000 cost of overtreatment per physician?* We believe accurate BP capture is so critical that we trademarked it. Better BP® is our proprietary, fully integrated point-of-care ecosystem using three innovations. https://ow.ly/oglG50TfzXu *Source: https://ow.ly/xiVz50TfAba